Abingdon Health Plc
public_traded
Abingdon Health Plc is publicly traded on LSE under ticker ABDX.L.
Abingdon Health Plc develops, manufactures, and distributes diagnostic devices worldwide. It offers AbC-19 Rapid Test, a COVID-19 IgG rapid antibody test; nucleic acid lateral flow immunoassays; Seralite, a rapid lateral flow test for the quantitative measurement of kappa and lambda immunoglobulin free light chains in serum; and AppDx, a customizable image capturing technology that transforms a smartphone into a self-sufficient and standalone lateral-flow reader. The company also provides lateral flow development and manufacturing services. Additionally, it provides consultancy services to businesses in the healthcare technology sector. The company has a collaboration and co-marketing agreement with Abcam plc. Abingdon Health Plc was incorporated in 2008 and is headquartered in York, the United Kingdom.